

PSMA PET/CT REQUISITION

Molecular Imaging and Therapy – Vancouver

PET Reception: (604) 707-5951

PET Fax: (604) 877-6245

Current Date: _____

Referring Physician: _____

Phone: _____

Fax: _____

Clinical Trial Information (if applicable)

Clinical Trial Name: _____

Contact Person: _____

Phone Number: _____

For Department use only

Scan Date: _____ Time: _____

Indication #: _____ 1 2

Details: _____

Routine: V-T: Other: _____

Date: _____ PET Dr. Initial: _____

Patient Information

Important:

Height: _____ Weight: _____ (kg / lb)

Mandatory:

PSA within last 3 months? **Value:** _____ **Date:** _____

Name: _____ Preferred Name: _____
Surname First Middle

Date of Birth: D _____ M _____ Y _____ PHN: _____

Home Address: _____

Home Phone: () _____ Work: () _____ Mobile: () _____

Temporary Address: _____ Temporary Phone: () _____

Family Physician: () _____ Phone: () _____

Patient Mobility: Ambulatory Wheelchair Stretcher

Diagnosis/Pertinent History

Indication for PSMA PET/CT Imaging (select one or more criteria below 1 - 6):

- 1) Localized prostate cancer considered for definitive therapy when conventional imaging is equivocal for metastatic disease.
- 2) NCCN high to very high risk localized prostate cancer with negative conventional imaging prior to consideration of curative intent therapy.
- 3) Clinically oligometastatic or oligoprogressive disease on prior imaging, being considered for metastases-directed therapy.
- 4) Localization of biochemical cancer Recurrent (BCR) or Persistent (BCP) prostate cancer following curative-intent therapy in the following settings*:
 - a. Pathologically node positive post RP with a PSA > 0.1 ng/mL at least 6 weeks after RP.
 - b. BCP with persistently elevated PSA > 0.1 ng/mL on first post RP PSA between 6 weeks and 3 months after Radical Prostatectomy when Gleason Grade Group (ISUP) 4-5.
 - c. BCR with a PSA > 0.2 ng/mL more than 6 weeks post Radical Prostatectomy when either PSA doubling time < 12 months OR Gleason Grade Group (ISUP) 4-5.
 - d. BCR with a PSA > 0.4 ng/mL more than 6 weeks post Radical Prostatectomy.
 - e. BCR post curative intent radiotherapy +/- adjuvant hormone therapy: i.e. a rise in PSA of ≥ 2 ng/mL above nadir.
 - f. BCR (Increase in PSA to ≥ 0.4 ng/mL) after prostatectomy and salvage radiotherapy +/- hormone therapy, where there is intent for further salvage therapy (e.g., SABR/metastases directed therapy).

- 5) **Castration resistant PC with evidence of biochemical or imaging progression.** Treatment does not need to be discontinued before the PET scan. Progression is defined by any of the following: A minimum PSA of 2.0 ng/mL and 2 consecutive rises above the nadir and castrate levels of testosterone (<1.7 nmol/L), soft tissue disease progression on chest, abdomen, pelvis CT or MR (RECIST v1.1), or bone progression ≥ 2 new lesions on bone scan.
- 6) **Clinical scenarios not included on this list but deemed appropriate after consensus at an appropriate BC Cancer Tumour Conference which includes expert imaging review. Describe below:**

***Notes:** i) Conventional staging should be considered when appropriate in each setting of criteria 4, if the PSA is very high, but is not a requirement prior to requesting PSMA PET.

ii) If the initial PSMA PET is negative, and no treatment is pursued, a second PSMA PET should not be requested for at least 6 months after the first scan unless recommended at appropriate BC Cancer Tumour Conference

Essential Information

Does patient require an interpreter?	Y <input type="checkbox"/> N <input type="checkbox"/>	Language: _____
Does patient have any drug allergies?	Y <input type="checkbox"/> N <input type="checkbox"/>	_____
CT scan within 3 months?	Y <input type="checkbox"/> N <input type="checkbox"/>	Date: _____
MRI scan within 3 months?	Y <input type="checkbox"/> N <input type="checkbox"/>	Date: _____
Nuclear Med scan within 3 months?	Y <input type="checkbox"/> N <input type="checkbox"/>	Date: _____
Previous PET or PET/CT scan?	Y <input type="checkbox"/> N <input type="checkbox"/>	Location/date: _____

Doctor's Signature: _____ **MSP No:** _____

Additional Copies of Report to: _____